Qingqing Yi - BeiGene Director
| BGNE Stock | USD 153.94 2.59 1.65% |
Director
Mr. Qingqing Yi is NonExecutive Independent Director of the company since October 2014. Mr. Yi is a Partner at Hillhouse Capital. He has worked with Hillhouse since the inception of the firm in 2005. Prior to joining Hillhouse, Mr. Yi was an Equity Research Analyst at China International Capital Corporationrationration. Mr. Yis work at Hillhouse includes investments in the healthcare and consumer sectors in both its public and private equity portfolios since 2014.
| Age | 45 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108 |
| Phone | 345 949 4123 |
| Web | https://www.beigene.com |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of May 1, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joseph Klein | Ionis Pharmaceuticals | 56 | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
| Joseph Loscalzo | Ionis Pharmaceuticals | 66 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Liz Anderson | Biomarin Pharmaceutical | N/A | |
| Willard Dere | Biomarin Pharmaceutical | 64 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| William Waddill | Arrowhead Pharmaceuticals | 60 | |
| Michael Mayer | Ascendis Pharma AS | 59 | |
| Elaine Heron | Biomarin Pharmaceutical | 70 | |
| Michael Perry | Arrowhead Pharmaceuticals | 57 | |
| Spencer Berthelsen | Ionis Pharmaceuticals | 65 | |
| Lynne Parshall | Ionis Pharmaceuticals | 63 | |
| James Healy | Ascendis Pharma AS | 53 | |
| Elizabeth Anderson | Biomarin Pharmaceutical | N/A | |
| Michael Grey | Biomarin Pharmaceutical | 65 | |
| Martin Olin | Ascendis Pharma AS | 48 | |
| Edwin Graaf | Ascendis Pharma AS | 42 | |
| Jacqualyn Fouse | Incyte | 56 | |
| Mauro Ferrari | Arrowhead Pharmaceuticals | 58 | |
| Rafaele Tordjman | Ascendis Pharma AS | 45 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, Chairman CoFounder | ||
| Howard Liang, CFO and Chief Strategy Officer | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Jason Yang, Senior Vice President Head of Clinical Development | ||
| Wang Lai, Global RD | ||
| Thomas Malley, Non-Executive Independent Director | ||
| Eric Hedrick, Interim Chief Medical Officer, Immuno-Oncology | ||
| Qingqing Yi, Director | ||
| Titus Ball, VP Officer | ||
| Julia Wang, CFO Officer | ||
| Hing Chau, Company Secretary | ||
| Daniel Maller, VP Accounting | ||
| Timothy Chen, Director | ||
| Wendy Yan, Senior Vice President Head of Regulatory Affairs | ||
| Ke Tang, Director | ||
| Xiaobin Wu, President COO | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Ranjeev Krishana, Director | ||
| Chan Lee, General VP | ||
| Donald Glazer, Director | ||
| Kevin Mannix, VP Relations | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Michael Goller, Director | ||
| JingShyh Su, Independent Director | ||
| Diana Francis, VP Compliance | ||
| Yan Qi, Senior China | ||
| Jane Huang, Chief Medical Officer, Hematology |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 210.56 B | ||||
| Shares Outstanding | 104.5 M | ||||
| Shares Owned By Insiders | 19.83 % | ||||
| Shares Owned By Institutions | 48.15 % | ||||
| Number Of Shares Shorted | 1.84 M | ||||
| Price To Earning | (16.19) X |
Pair Trading with BeiGene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BeiGene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BeiGene will appreciate offsetting losses from the drop in the long position's value.Moving against BeiGene Stock
| 0.55 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.46 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to BeiGene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BeiGene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BeiGene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BeiGene to buy it.
The correlation of BeiGene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BeiGene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BeiGene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BeiGene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.45) | Revenue Per Share 23.554 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.22) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.